After transformation, survival rates varied by original cancer type, with the poorest prognosis for those transformed from CLL/SLL and from LPL/WM.

Consistent with prior reports, outcomes were very poor. The median overall survival (OS) was 3.4 months (95% confidence interval [CI] 2.9 to 4.2); sex had no impact, but age >70 years was ...

Diffuse large B-cell lymphoma is the most common type of lymphoma. It makes up approximately 25% of all non-Hodgkin’s lymphomas, which are cancers that lack defining cells called Hodgkin cells ...

HYDERABAD: The first FDA-approved therapy for first-line treatment of Diffuse Large B-cell lymphoma (DLBCL) has been brought to India. A new antibody-drug conjugate (ADC) Polatuzumab combined with ...

Epcoritamab demonstrates efficacy in CAR T-naïve B-cell lymphoma patients, with 61% overall response and 45% complete response rates. Median progression-free survival and overall survival were ...

Biotech J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients By Darren Incorvaia Jun 13, 2025 1:22pm Johnson & Johnson CAR-T Cell & Gene Therapy B-cell lymphoma ...

The Food and Drug Administration (FDA) has approved Adcetris ® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory (R/R ...

The real-world effectiveness of Monjuvi (tafasitamab-cxix) in U.S. patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) was confirmed, along with factors associated with survival ...